Biostar Pharmaceuticals Airs Advertisements for its Analgesic (Pain Relief) Cream on China's CCTV

Feb 16, 2016, 09:00 ET from Biostar Pharmaceuticals, Inc.

XIANYANG, China, Feb. 16, 2016 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar"), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 5, 2016, before the busy Chinese Lunar New Year, the first TV advertisement for the Company's product, Speranskia Analgesic Cream, was broadcast on China's Central Television news channel (CCTV-1) as a part of the Company's advertising campaign.

CCTV-1 broadcasts a range of programs and is available to television viewers from Beijing, China. As part of CCTV Network, China's only state owned national broadcasting television station, CCTV-1 is the most influential media outlet in China with one of the highest viewership and ratings.

Speranskia is a plant genus of the family Euphorbiaceae, with the entire genus endemic to China. The Company developed a cream formulation that is intended to joint pain relief by topical application of the cream; the Company holds a PRC patent for the cream formulation. The TV advertisement for this product is the first of its kind relating to the Company's products to appear on China's TV broadcasts. The purpose of this advertisement effort was to increase the Company's profile and widen its brand/product recognition. The Company anticipates repeated broadcasts of the TV advertisement for this product after February 20, 2016.

Mr. Ronghua Wang, Chairman and CEO of Biostar, commented: "We are excited to have launched the advertising campaign on CCTV during one of most watched TV seasons in China. This is the first time a Biostar product was featured on a national level. We are hopeful that the CCTV exposure will increase brand and product recognition of the Company and its product line."

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. For more information please visit:

Safe Harbor relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding our ability to achieve the expected market interest in the Company's product line following the advertising campaign, the Company's ability to comply with the Nasdaq continued listing requirements, to achieve its growth strategy, incorporate and successfully develop additional drugs into the Company's existing product portfolio, its ability to capitalize on the market opportunities presented by such acquisition, regulatory and other related approvals relating to the acquisition, the Company's ability to integrate this acquisition into its current operations, its ability to complete the audit and other closing conditions relating to the acquisition,  success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2014, and other subsequent public filings. These filings are available at We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

Investor Relations Contact

Please send questions or comments to:

Biostar Pharmaceuticals, Inc. Investor Relations Coordinator +86-29-3368-6638

SOURCE Biostar Pharmaceuticals, Inc.